Request a Quote |

AGM Statement

Cyprotex PLC ("Cyprotex" or the "Company")

Cyprotex (AIM:CRX), the drug discovery technology and information company, will hold its Annual General meeting today. At that meeting, Steve Harris, Chairman, will make the following comments:

"In 2009 we delivered a resilient performance in a difficult market. Revenues hit £5m for the second successive year and we also delivered our second year of profitability. We doubled the number of strategic customers and added 20 new customers in total.

"In the current year, Cyprotex has experienced a strong second quarter and this momentum has continued into July. The Company's revenue and EBITDA performance is in line with market expectations. Furthermore, the Company will open a new laboratory in the coming weeks which will double capacity and allow the launch of our new toxicology offerings."

Cyprotex expects to announce its interim results for the six months to 30 June 2010 on Thursday 12 August 2010.

For further information:
Cyprotex PLC
Dr Anthony Baxter, Chief Executive Officer
John Dootson, Chief Financial Officer
Tel: +44 (0) 1625 505 100

Singer Capital Markets Ltd
Shaun Dobson
Claes Spång
Tel: +44 203 205 7500

Financial Dynamics
Ben Brewerton / Ben Atwell / Mo Noonan
Tel: +44 (0) 20 7831 3113

Contact us

News categories


Contact us to discuss your ADME Tox issues or request a quote

North America (East Coast): +1-888-297-7683
Europe: +44 (0)1625 5051000


or fill out the form below:

Please give details of the assays you are interested in. Where appropriate please specify one or more species (human, rat, mouse etc.), isoforms (CYP1A1,CYP1B1, etc) or other relevant details.

By clicking on ‘Send’ I agree that my data is being transferred and used by Cyprotex and the affiliated Evotec Group. The Evotec Group currently consists of the following companies. For further details please see our privacy policy.

If you would like to be kept informed of our latest services, new research, events and other news please tick the box below: